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Interest in amiodarone has increased because of its re-
markable efficacy as an antiarrhythmic agent. The pur-
pose of this report is to review what is known about the
electrophysiologic actions, hemodynamic effects, phar-
macokinetics, alterations of thyroid function, response
to treatment of supraventricular and ventricular tachy-
arrhythmias and adverse effects of amiodarone. Un-
derstanding the actions of amiodarone and its metabo-
lism will provide more intelligent use of the drug and
minimize the development of side effects.
The mechanism by which amiodarone suppresses car-
diac arrhythmias is not known and may relate to pro-
longation of refractoriness in all cardiac tissues, suppres-
sion of automaticity in some fibers, minimal slowing of
conduction in fast channel-dependent tissue, or to in-
teractions with the autonomic nervous system, altera-
tions in thyroid metabolism or other factors. Amioda-
rone exerts definite but fairly minor negative inotropic
effects that may be offset by its vasodilator actions.
Amiodarone (Fig. I) is a benzofuran derivative (l) that was
initially developed to treat angina pectoris in patients with
coronary artery disease (2). In fact, the drug was moderately
successful as an antianginal agent. Further experience with
amiodarone revealed it to be a very effective antiarrhythmic
agent for treating patients with supraventricular (3) and ven-
tricular (4) tachyarrhythmias. Since our last review of sev-
eral new antiarrhythmic agents (5), we have treated with
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Amiodarone has a reduced clearance rate, large volume
of distribution, low bioavailability and a long half-life
that may last 2 months in patients receiving short-term
therapy. Therapeutic serum concentrations range be-
tween 1.0 and 3.5 ILg/ml.
The drug suppresses recurrences of cardiac tachyar-
rhythmias in a high percent of patients, in the range of
80% or more for most supraventricular tachycardias
and in about 66% of patients with ventricular tachyar-
rhythmias, sometimes requiring addition of a second
antiarrhythmic agent. Side effects, particularly when
high doses are used, may limit amiodarone's usefulness
and include skin, corneal, thyroid, pulmonary, neuro-
logic, gastrointestinal and hepatic dysfunction. Aggra-
vation of cardiac arrhythmias occurs but serious ar-
rhythmias are caused in less than 5% of patients.
Amiodarone affects the metabolism of many other drugs
and care must be used to reduce doses of agents com-
bined with amiodarone.
amiodarone more than 400 patients referred because of a
variety of drug-resistant supraventricular and ventricular
tachyarrhythmias. At the time of that review, knowledge of
amiodarone's pharmacokinetics, multiple actions and ad-
verse effects was preliminary. We indicated that its antiar-
rhythmic action persisted 30 to 45 days after discontinuation
of drug therapy and mentioned briefly that amiodarone non-
competitively blocked both alpha- and beta-adrenergic re-
ceptors, that it increased action potential duration in a variety
of tissue types with little or only a slight depressant effect
on phase 0 conduction in fast channel tissues and that it
decreased the sinus discharge rate, prolonged the QT and
AH intervals and lengthened the refractory period of all
tissue types. Few adverse effects were listed, including skin
discoloration, hyperthyroidism, hypothyroidism. occasional
neurologic side effects and corneal microdeposits. In the
interval since that study, researchers throughout the world
have become interested in this fascinating and unique an-
tiarrhythmic agent. and have dramatically increased our
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Figure 1. Formula for amiodarone.
knowledge of amiodarone's electrophysiologic actions,
pharmacokinetics and clinical effects. The purpose of this
review is to summarize some of those data.
Electrophysiologic Actions
The most profound direct electrophysiologic action of
amiodarone on cardiac fibers is to prolong repolarization
and refractoriness in all cardiac tissue studied, including the
sinus node, atrium, atrioventricular (AV) node, His-Pur-
kinje system and ventricle (6). Amiodarone also depresses
impulse initiation in the isolated rabbit sinus node (7).
Purkinje system. Recent data (8,9) suggest that amio-
darone depresses phase 0 in Purkinje fibers and that this
use-dependent effect appears to result from selective block-
ade of inactivated sodium channels. However, in vitro data
of amiodarone should be accepted with caution because of
the difficulty of dissolving amiodarone into solution. Never-
theless, the observation is consistent with clinical data. In
our experience, orally administered amiodarone prolongs
the HV interval in patients by about 15 to 20%.
Sinus and AV nodes. No studies of amiodarone' s action
on the slow response action potential have been reported.
However, the lack of significant effect of amiodarone on
sinus and AV nodal action potentials, other than to prolong
repolarization and refractoriness and depress sinus nodal
discharge rate, suggest that therapeutic concentrations may
not have a major effect in suppressing the slow response
(6).
Amiodarone depresses sinus nodal and junctional auto-
maticity and intranodal conduction when injected into the
respective sinus and AV nodal arteries in anesthetized dogs.
Propranolol or atropine did not influence these changes, but
a low calcium concentration in the perfusate enhanced the
negative chronotropic effects (10).
Intravenous versus oral administration. Amiodarone
given intravenously to animals and human beings produces
no significant alterations in the QTc interval despite myo-
cardial concentrations after single intravenous doses in an-
imals that are comparable with those after prolonged oral
administration (11). Orally administered amiodarone sig-
nificantly prolongs the QTc interval (12). Prolongation of
AV nodal refractoriness is greater after oral administration
than after intravenous administration of amiodarone. A marked
increase in the effective refractory periods of all cardiac
tissues follows chronic oral therapy while little or no pro-
longation results after single intravenous bolus injections
except in AV nodal fibers. Suction electrodes recording
monophasic atrial action potentials have demonstrated pro-
longation after amiodarone treatment in human beings (13).
Response to adrenergic stimulation. Amiodarone dis-
solved in ethanol and added to homologous blood plasma
noncompetitively antagonizes the chronotropic responses of
rabbit atria to isoproterenol (14). It also inhibits norepi-
nephrine-induced contractions of myocardial strips in rats
and rabbits, but does not affect potassium-depolarized con-
tractions of mammalian aortic strips. Amiodarone exerts an
antisympathetic effect on both alpha- and beta-adrenergic
responses to sympathetic stimulation or catecholamine in-
jection (15). Amiodarone also inhibits release of neurotrans-
mitter from presynaptic adrenergic neurons (11).
Hemodynamic Actions
Experimental effects. Amiodarone, 5 mg/kg intrave-
nously in dogs, reduced systemic vascular resistance and
mean arterial pressure with no change in left ventricular end-
diastolic pressure, first derivative of left ventricular pressure
(dP/dt) or contractile force. However, 10 mg/kg increased
left ventricular filling pressure and reduced contractility.
Intracoronary injections in dogs produced approximately
70% of the peak coronary vasodilator effects of an intra-
coronary injection of nitroglycerin (6 /Lg) (11).
Amiodarone given intravenously at a dose of 10 mg/kg
in a single bolus 30 minutes after coronary artery occlusion
in dogs decreased heart rate, contractility and afterload, and
reduced mean aortic pressure, left ventricular peak pressure,
left ventricular dP/dt, maximal negative dP/dt but did not
change left ventricular end-diastolic pressure. Cardiac out-
put may increase despite the negative inotropic effect be-
cause of the more pronounced concomitant reduction of
systemic vascular resistance and impedance to left ventric-
ular ejection (16).
Clinical effects. In patients without depressed left ven-
tricular function undergoing diagnostic cardiac catheteriza-
tion, amiodarone, 5 mg/kg intravenously, reduced mean ar-
terial pressure, left ventricular end-diastolic pressure and
systemic vascular resistance and slightly increased cardiac
index. Coronary vascular resistance decreased and coronary
sinus flow increased. Despite the decrease in systemic vas-
cular resistance, a reflex increase in heart rate did not occur,
consistent with the drug's antiadrenergic effects (17).
Oral doses of the drug sufficient to control cardiac ar-
rhythmias do not depress left ventricular ejection fraction
measured by radionuclide ventriculography. Because amio-
darone rarely aggravates hemodynamic function even in
patients with compromised left ventricular contractility, mi-
nor negative inotropic effects may be offset by the potent
vasodilator properties of the drug even in patients with com-
promised left ventricular contractility. However, in patients
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with compensated cardiac failure critically dependent on
augmented sympathetic drive, the nonspecific antisympath-
etic effect of amiodarone may produce hemodynamic de-
terioration (11).
In patients with depressed left ventricular function and
recurrent ventricular tachycardia, amiodarone given intra-
venously at a loading dose of 5 mg/kg body weight over
20 minutes resulted in a linear decrease in heart rate, a
reduction in stroke work index and cardiac index, without
any significant change in systemic vascular resistance or
pulmonary capillary wedge pressure. Depression of left ven-
tricular function was mild and transient and well tolerated,
except in two patients with overt heart failure and severely
depressed left ventricular ejection fraction, who developed
profound hypotension. Transient deterioration of left ven-
tricular contractility was more apparent in patients with se-
verely depressed left ventricular function, probably resulting
from the negative inotropic effects of amiodarone. In most
patients this depression was transient and not severe. The
decrease in contractility that tends to decrease cardiac output
appears to be balanced by afterload reduction which in-
creases cardiac output, resulting in either no change or only
a slight transient deterioration of left ventricular function
(18).
After protracted oral amiodarone therapy, no significant
change in left ventricular ejection fraction measured by
radionuclide ventriculography has been noted. Although well
controlled studies on the hemodynamic effects of chroni-
cally administered oral amiodarone are lacking, present data
(19) suggest that the drug does not have severe negative
inotropic effects of clinical significance in most patients.
From these data it is apparent that amiodarone may be
administered to patients with compromised left ventricular
function. In addition, amiodarone may be useful in patients
who have coronary disease and exercise-induced angina (2)
or even atypical angina (20).
Pharmacokinetics
BioavailabiIity, clearance rate and half-life. Amio-
darone has a reduced clearance rate, large volume of dis-
tribution, low bioavailability and a long half-life. The low
bioavailability may relate to incomplete intestinal absorption
while the larger volume of distribution and reduced clear-
ance contribute to the long elimination half-life. Amioda-
rone may be released slowly from a reservoir or poorly
perfused deep compartment such as fat into the plasma.
After intravenous administration of 400 mg amiodarone to
healthy young male volunteers, total plasma clearance was
about 8.5 liters/h, total blood clearance about 12 Iiters/h,
with a steady state distribution volume of approximately
5,000 liters. Terminal elimination half-life was 25 days after
single dosing and oral bioavailability 35%. Renal elimi-
nation of both amiodarone and its metabolite desethylamio-
darone was negligible. Clearance of amiodarone decreases
with time and it is possible, based on the fact that amio-
darone decreases the clearance of other drugs, that amio-
darone decreases its own clearance. Terminal elimination
half-life of the major metabolite, desethylamiodarone, was
similar to that of the parent compound (21).
Plasma concentration and elimination half-life. In 170
patients receiving maintenance amiodarone therapy, a daily
dose of 200 mg produced a plasma concentration of ap-
proximately 1.0 j.Lg/ml. A dose of 400 mg daily resulted in
plasma concentrations of approximately 2.0 j.Lg/ml and 600
mg, approximately 3.5 j.Lg/ml. Terminal elimination half-
life after cessation of chronic therapy was about 53 days
for the parent compound and 61 days for the metabolite.
Patients appear to have a longer elimination half-life than
volunteer subjects, but the range is wide: 13 to 107 days
after chronic therapy (21). Both parent drug and metab-
olite have been measured in plasma more than 9 months
after cessation of therapy. The long terminal phase of elim-
ination prolongs the time taken to attain steady state tissue
concentrations. An excess of 10 days may be required to
achieve equilibration in the slowly penetrated tissues. Of
interest, in the first few days after cessation of therapy,
plasma concentrations decreased comparatively rapidly, fol-
lowed by a rebound peak 12 to 21 days after stopping treat-
ment. This biphasic elimination pattern of amiodarone, pos-
sibly due to rapid clearance from well perfused tissues of
the central compartment with slower elimination from poorly
perfused tissue compartments, may necessitate frequent
maintenance dosage intervals despite such a prolonged ter-
minal elimination half-life. The concentration of the des-
ethylamiodarone metabolite exceeds that of amiodarone in
all tissues except those in which the amiodarone concen-
trations are high (for example, fat, approximately 300 mg/kg
wet weight) where the concentration of amiodarone exceeds
the concentration of the metabolite (21).
Loading dose and daily dose schedule. These data sug-
gest that a large loading dose should be used when beginning
amiodarone therapy because the large volume of distribution
would be expected to delay the time to achieve minimal
effective drug concentrations within the body and thus delay
the time to onset of clinical efficacy. A loading regimen
appears to decrease the time of onset of antiarrhythmic ac-
tion (22).
As might be expected, a daily dose schedule of 1,600
mg/day produces significantly higher drug concentrations
than 800 mg/day. After 15 days, patients receiving 800
mg/day achieved an amiodarone plasma concentration of
1.7 j.Lg/ml while those receiving 1,600 mg/day had 2.7
j.Lg/ml. The ratio of desethylamiodarone to amiodarone in
both plasma and red cells increased progressively with time,
reaching about 0.5 in plasma but 1.5 to 2 in red cells after
15 days for both doses. During chronic amiodarone admin-
istration, with doses of 200 to 600 mg/day, the mean ratio
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of desethylamiodarone to amiodarone increased to 0.78 in
plasma and to 2.4 in red blood cells samples. Plasma amio-
darone concentrations after 200,300,400 and 600 mg amio-
darone/day long-term were 1.4, 1.5, 2.3 and 2.9 ILg/ml,
respectively. These data indicate that a direct relation exists
between size of the daily loading dose of amiodarone and
plasma or red blood cell concentration. The rate of formation
of desethylamiodarone appears to be time dependent. A
linear correlation results between plasma concentrations of
drug and metabolite (23).
Distribution, equilibrium and dosage. Approximately
20 to 60% of an oral dose of amiodarone enters the systemic
circulation with maximal plasma concentration achieved 4
to 5 hours after drug ingestion. Amiodarone is then distrib-
uted throughout the body to achieve an equilibrium between
tissues and plasma. The time course of the equilibrium varies
greatly among different tissues (21,24,25).
Amiodarone exhibits heterogeneous distribution and
equilibrium and is better described by models with three or
four compartments. A compartment is a pharmacokinetic
rather than an anatomic entity, reflecting the characteristics
of drug uptake and release by a group of tissues in the body.
Tissues with different characteristics would be included in
different compartments. Amiodarone may have a "deep"
peripheral compartment such as fat or other poorly perfused
tissues having an affinity for lipid-soluble drugs, with which
equilibrium is achieved very slowly. The concentration of
amiodarone in the central (well perfused) compartment in-
creases rapidly to reach steady state levels within I day
while the accumulation of drug in peripheral compartments
is slow, requiring several days to a week to reach steady
state levels. Based on known pharmacokinetics, a theoret-
ical regimen calculated to achieve a plasma amiodarone
concentration of 1.5 ILg/ml, assuming approximately 50%
bioavailability, might be 2 g during the first day and then
1,400 mg/day for three days, 1,000 mg/day for one week,
800 mg/day for 2 weeks, 600 mg/day for 4 weeks and then
400 mg alternating with 600 mg/day maintenance. Amio-
darone would be given in divided doses of 600 mg or less
(26).
Chronic therapy: plasma concentrations and dos-
age. Because amiodarone pharmacokinetics may change with
time, monitoring plasma concentrations during chronic
treatment may give important information about the relation
between drug concentration and effect and allow develop-
ment of more definite guide lines for safe chronic therapy.
The wide range of reported bioavailability could lead to
toxic accumulation of drug in some patients. Plasma con-
centrations may not be helpful or may be misleading during
the 4 to 6 week loading period at the beginning of treatment
(26).
The therapeutic level ofserum concentrations varies, but
appears to range between 1.0 and 3.5 ILg/ml. In one study
(27) of 96 patients with life-threatening ventricular tachy-
arrhythmias and 77 patients with a variety of supraven-
tricular tachyarrhythmias resistant to conventional antiar-
rhythmic agents in therapeutic doses, amiodarone was judged
effective in approximately 80% of patients followed up for
10 months by preventing recurrence of symptoms of the
arrhythmia or by producing greater than 80% decrease of
high grade ventricular ectopic activity during ambulatory
electrocardiographic monitoring. Maintenance amiodarone
serum concentrations ranged from 0.6 to 2.8 ILg/ml (mean
1.6 in the responders with a wide intersubject variation of
serum concentrations for a given dose of amiodarone). Ar-
rhythmia relapses occurred in nine patients when their serum
concentration decreased to less than 1.0 ILg/ml. In eight of
these patients, reinstitution of higher amiodarone dosages
and elevation of serum amiodarone concentration again sup-
pressed their arrhythmias. Thus, there appears to be a good
relation between dosage and steady state concentration of
amiodarone. However, the reported data (27) indicate con-
siderable overlap of concentrations both for therapeutic ef-
ficacy as well as for those concentrations associated with
toxicity.
Treatment of Arrhythmias
Supraventricular Tachyarrhythmia
Amiodarone is effective therapy for patients who have a
wide variety of supraventricular tachyarrhythmias. As with
ventricular tachyarrhythmias the exact percentage of success
varies, influenced in part by whether a group of patients
represent a selected group with drug-resistant arrhythmias.
Nevertheless, data from sufficiently diverse studies indicate
that amiodarone effectively suppresses recurrences of supra-
ventricular tachycardia in 80% or more of the patients treated
(3,4,28,29).
Dosage and effectiveness. In contrast to patients re-
ceiving the drug for ventricular arrhythmias, lower loading
and maintenance doses appear to be necessary to control
supraventricular tachycardias (30,31). For example, in one
study, suppression of supraventricular arrhythmias required
280 to 350 mg/day versus 400 to 440 mg/day for ventricular
arrhythmias (30). In another (29), about 50% of 121 patients
needed 200 mg/day of amiodarone to suppress recurrences
of supraventricular tachyarrhythmias while only 6% re-
quired a 600 mg daily maintenance dose. No differences in
serum concentration of the parent drug were noted among
responders and nonresponders. Side effects were generally,
but not invariably, associated with a higher average serum
concentration (2.3 ILg/ml) than necessary for control of ar-
rhythmia. However, there was much overlap in dose and in
serum concentration between those with and without side
effects. Of 95 patients with atrial fibrillation or atrial flutter,
74 had an effective response (arrhythmia prevented for at
least 6 months) and six had a partial response (recurrence
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but at longer intervals with episodes more abbreviated and
self-terminating). In 15 patients, amiodarone was ineffec-
tive. In 26 patients who had a presumed reentrant supra-
ventricular tachycardia, in 9 associated with an accessory
pathway, amiodarone was effective in 24, partially effective
in I and ineffective in 1. Thus, 105 (86.7%) of 121 patients
receiving amiodarone experienced complete or partial con-
trol of their clinical arrhythmia. Ninety-eight patients (81 %)
had complete suppression of symptomatic recurrence over
an average follow-up of 27 months. Seven patients had a
partial response, 16% were failures and significant side ef-
fects required discontinuation of therapy in eight patients
(29).
WoltT-Parkinson-White syndrome with circus move-
ment tachycardia. In 30 patients with Wolff-Parkinson-
White syndrome and the usual (orthodromic) form of circus
movement tachycardia receiving a total of 11.2 to 14 g of
amiodarone over 6 to 8 weeks of therapy (32), refractory
periods of the atrium, AV node, His-Purkinje system, ven-
tricle and accessory pathway prolonged. Programmed stim-
ulation of the heart in these 30 patients revealed that the
arrhythmia could no longer be initiated in nine due to marked
prolongation of the refractory period or block in the acces-
sory pathway retrogradely (four patients), block in the AV
node (four patients) or block between the His bundle and
ventricle (one patient). Thus, the weak link in the reentry
circuit after amiodarone administration differed from patient
to patient. Four patients showed spontaneous termination
of circus movement tachycardia that did not occur before
amiodarone therapy, due to block in the AV node (two
patients) or accessory pathway (two patients). In the 23
patients in whom circus movement tachycardia could still
be initiated after amiodarone treatment, the rate of the tachy-
cardia slowed with a mean increase in RR interval of 85
ms (32). Although tachycardia was still initiated in 21 pa-
tients by programmed electrical stimulation, follow-up (8
to 70 months, mean 40) revealed that spontaneous episodes
of tachycardia occurred in only four patients. This finding
suggests that the therapeutic efficacy of amiodarone in these
patients may be based, in part, on prevention of tachycardia-
initiating premature beats. The weekly dose of amiodarone
required to control the arrhythmia was 500 mg in four pa-
tients, 700 to 1,400 mg in 2I patients and more than 1,400
mg in only two patients. Side effects did not necessitate
termination of amiodarone administration in any patient (32).
WoltT-Parkinson-White syndrome with atrial fibril-
lation. In these patients, symptoms produced by the ar-
rhythmia primarily relate to the duration of the anterograde
refractory period of the accessory pathway, which in large
part determines the ventricular rate. The extent of length-
ening of the duration of the refractory period of the accessory
pathway anterogradely after amiodarone is related to the
duration of the refractory period before treatment. When
the duration of the control refractory period is short, amio-
darone lengthens it very little. Complete anterograde block
in the accessory pathway after ajmaline or procainamide
administration predicts an increase of 100 ± 85 ms in the
anterograde effective refractory period of the accessory
pathway after amiodarone administration, which is twice
the increase observed in patients with a negative ajmaline
or procainamide test. However, amiodarone may also be
efficacious by preventing recurrences of the arrhythmia. For
example, amiodarone administered to 17 patients with re-
current episodes of atrial fibrillation terminated recurrences
in 13 patients (mean follow-up 50 months) while 4 patients
continued to have paroxysmal episodes of atrial fibrillation
requiring surgical interruption of the accessory pathway in
2 (33).
Resistant supraventricular tachycardia. AV nodal
reentrant tachycardia resistant to other antiarrhythmic drugs
may respond chronically to relatively small doses of amio-
darone (4,28,34). Patients with supraventricular tachyar-
rhythmias more difficult to control may be those who have
so-called "incessant" supraventricular tachycardia related
to a concealed accessory pathway and those with a "per-
manent" form of reciprocating tachycardia (31). Patients
with atrial fibrillation difficult to control may be those who
have episodes of atrial fibrillation precipitated during phys-
ical exertion that tend to recur during activity rather than
during sleep or rest (35). In treating this form of atrial
fibrillation, beta-adrenergic receptor blocking drugs may be
more effective than amiodarone. In some patients after con-
trol of the atrial fibrillation for several weeks, the tendency
to develop new episodes may be reduced so that much lower
doses of amiodarone may provide subsequent control (31).
Ventricular Tachyarrhythmia
Data from a large number of studies attest to clinical
efficacy of amiodarone in suppressing spontaneous ventric-
ular tachyarrhythmias. Amiodarone consistently reduces the
number of spontaneous premature ventricular complexes
and episodes of ventricular tachycardia determined by am-
bulatory recordings. The percent reduction in ventricular
ectopic complexes varies in different studies but generally
exceeds 80%. Larger maintenance doses of amiodarone may
be required to suppress episodes of ventricular tachycardia
than to suppress premature ventricular complexes (31).
Therapeutic latency. When amiodarone is discontinued
after a given time, the antiarrhythmic protection lasts for
several days, weeks or even months (4). A therapeutic "la-
tency" exists before the maximal antiarrhythmic effects (as
well as many adverse effects) are obtained with amiodarone.
Initial therapeutic latency varies in most cases from 5 to 15
days but full suppression of arrhythmia may not be reached
until 15 to 30 days, or more, of treatment. Interestingly,
the average heart rate at rest commonly continues to slow
until the third and sometimes even the fourth or fifth month
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of therapy, suggesting a continued "building up" of amio-
darone effects, at least on sinus rate. Patients with sustained
recurrent symptomatic ventricular tachycardia may require
at least 8 to 10 days of drug administration to achieve control
of the arrhythmia (12,31). Clinical studies suggest that the
more difficult it is to control a given arrhythmia, the longer
the latency to achieve suppression and shorter the persis-
tence of effects after drug discontinuation. Conversely, in
patients with more easily controlled arrhythmias, latency is
shorter, duration of drug effects is longer, and often less
drug is required to maintain suppression of the arrhythmias.
The latency appears to be short in children (36).
Results in recurrent ventricular tachycardia. We have
recently evaluated (37) our study group of 196 patients
(mean age 56 years; 154 men) who began amiodarone treat-
ment for recurrent ventricular tachycardia or ventricular fi-
brillation and who had at least I month of follow-up before
December 31, 1982. One hundred twenty-nine patients had
ischemic heart disease and 35 patients had idiopathic dilated
cardiomyopathy. The remainder had a variety of diagnoses.
On the basis of New York Heart Association criteria, 25
patients were in functional class I, 112 in class II, 54 in
class III and 5 in class IV according to symptoms and signs
of congestive heart failure. Recurrent sustained ventricular
tachycardia, defined as ventricular tachycardia that produced
syncope, required electrical cardioversion or lasted longer
than 30 seconds, was present in 95 patients. In 44 patients,
recurrent ventricular tachycardia was nonsustained. Fifty-
seven patients had experienced one or more episodes of
cardiac arrest due to ventricular fibrillation that required
cardiopulmonary resuscitation. Each patient had received 2
to 10 (mean 4.4 ± 1.9) drug trials before amiodarone treat-
ment. Of 863 prior drug trials, 798 had failed because of
recurrence of ventricular tachycardia or ventricular fibril-
lation and 105 patients had required cardioversion or defi-
brillation during prior drug trials (37).
Amiodarone was administered at a dose of 800 mg/day
for 4 to 8 weeks. The dose was decreased at 3 month in-
tervals to 200 to 600 mg/day if the arrhythmia remained
suppressed. Patients who entered the investigation during
the last 6 months of the study period received an initial
amiodarone dose of 1,600 mg/day for the first 2 weeks of
treatment, then 800 mg/day with gradual reduction to 200
to 600 mg/day.
During a mean follow-up time of 16.2 ± 13.0 months
(range 1 to 57), 126 (64%) of 196 patients continued to
receive amiodarone treatment, including 35 (61 %) of 57
who had recurrent ventricular fibrillation, 59 (62%) of 95
who had recurrent sustained ventricular tachycardia and 32
(73%) of 44 who had recurrent nonsustained ventricular
tachycardia. The results after the initial month of amioda-
rone treatment are outlined in Table I, while the outcome
of long-term (16.2 ± 13.0 months) amiodarone treatment
in 177 patients is outlined in Table 2. No recurrence of
spontaneous ventricular tachycardia or ventricular fibrilla-
tion was evident in 139 patients, of whom 112 have con-
tinued long-term treatment. Ventricular tachycardia or ven-
tricular fibrillation recurred in 38 patients but amiodarone
was continued in 17 of these patients, usually along with a
dosage change, addition of another drug or insertion of an
electrical device. During continued follow-up of these 17
patients, 3 died from congestive heart failure that antedated
onset of amiodarone treatment and 14 have continued amio-
darone treatment.
Of 126 patients receiving long-term amiodarone treat-
ment, 41 have had the following antiarrhythmic drugs added
to amiodarone: aprindine in 12, aprindine and propranolol
in 1, quinidine in 10, encainide in 6, disopyramide in 5,
mexiletine in 2, mexiletine and propranolol in I, propranolol
alone in 2, procainamide in I and propafenone in I. In no
patient did a drug combination appear to result in exacer-
bation of ventricular arrhythmia or congestive heart failure
but doses of both amiodarone and the added drug were
reduced, often by 50%. During the course of treatment,
amiodarone was discontinued in 12 patients because of non-
cardiac adverse effects: pulmonary toxicity in 5, nausea and
anorexia in 4, tremor and ataxia in I, urinary retention in
I and hyperthyroidism in I patient. A permanent pacemaker
was implanted in four patients who developed symptomatic
bradyarrhythmias during amiodarone treatment (37).
Amiodarone treatment appeared to exacerbate ventric-
ular arrhythmia in nine patients (Table 3). Patient 5, who
was taking digoxin, was the only patient receiving other
cardioactive drugs. In Patients 2, 8 and 9, multiple other
antiarrhythmic drugs were associated with exacerbation of
arrhythmias. In all nine patients, the amiodarone-associated
arrhythmias resolved within 2 to 3 days after discontinuation
of amiodarone (37). Arrhythmias associated with amioda-
rone treatment have been noted by others as well (38-42),
but their frequency appears to be less than with most other
antiarrhythmic agents.
Role of electrophysiologic studies. In our patients elec-
trophysiologic studies were performed after at least 2 weeks
of amiodarone treatment in 101 patients who had ventricular
tachycardia induced at control study and in 17 patients who
did not undergo a control study before drug administration
(37). Of the 101 patients who had serial electrophysiologic
studies, amiodarone was discontinued in 2 patients after
induction of sustained ventricular tachycardia. In 15 pa-
tients, including 2 who had amiodarone combined with quin-
idine because of spontaneous ventricular tachycardia, amio-
darone prevented ventricular tachycardia induction at repeat
electrophysiologic study. None of these 15 patients had
recurrent ventricular tachycardia during long-term amio-
darone treatment.
In the other 84 serially studied patients and in 17 patients
who did not have a control electrophysiologic study, pro-
grammed electrical stimulation during amiodarone treatment
JACC Vol. 3. No.4
April 1984: 1059-71
ZIPES ET AL.
AMIODARONE
1065
Table 1. Outcome of Initial Treatment of Ventricular Arrhythmias With Amiodarone for 1 Month in 196 Patients
Group
I
II
III
IV
Total Patients (no.)
107
73
13
3
Response
No spontaneous VT or VF
Recurrent spontaneous VT or VF
Treatment change due to VT induced
at EP study
Amiodarone discontinued
Adverse side effects
Death from congestive heart failure
Treatment
Type
Amiodarone continued
Amiodarone continued alone
Antiarrhythmic agent added
Amiodarone discontinued
Antiarrhythmic agent added
Amiodarone discontinued
Patients
107
8
51
14
II
2
2
I
EP = electrophysiologic; VF = ventricular fibrillation; VT = ventricular tachycardia. Adapted from Heger 11. Prystowsky EN. Zipes DP (37) with
permission of the American Heart Journal.
Table 2. Outcome of Long-Term Treatment of Ventricular Arrhythmias With Amiodarone
Group
II
Total Patients (no.)
139
38
Response
No spontaneous VT or VF
Recurrent VT or VF
Treatment
Type
Amiodarone continued
Amiodarone discontinued due to
Adverse side effects
Death from CHF
Noncardiac death
Sudden cardiac death
Amiodarone discontinued
Amiodarone continued
Patients
112
10
16
I
15
6
17*
*Three of these patients died from congestive heart failure.
CHF = congestive heart failure; VF = ventricular fibrillation: VT = ventricular tachycardia.
Reproduced from Heger 11, Prystowsky En. Zipes DP (37) with permission of the American Heart Journal.
Table 3. Amiodarone-Associated Exacerbation of Ventricular Arrhythmias
Amiodarone
Pretreatment Treatment Successful Follow-up
Patient Arrhythmia (wks) Arrhythmias Treatment (mo)
VT-S 4 Polymorphic VT: Mexiletine 6
syncope
2 VF 2 Incessant VT-NS Propranolol 14
3 VT-S 2 Incessant VT-S: Quinidine 14
multiple DC shocks
4 VT-NS 2 VF Mexiletine 19
5 VT-S 2 VF Mexiletine 33
6 VT-S 2 Continuous VT: Tocainide 18
temporary pacer
7 VT-S 2 VF Mexiletine 39
8 VT-NS I Incessant VT-S Propranolol 8
9 VT-S I Incessant VT-S Tocainide -t 40
propranolol
DC = direct current: VF = ventricular fibrillation; VT-NS = nonsustained ventricular tachycardia; VT-S
Adapted from Heger 11, Prystowsky EN, Zipes DP (37) with permission of the American Heart Journal.
sustained ventricular tachycardia.
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induced ventricular tachycardia but amiodarone treatment
was continued. Of these 101 patients, 80 have continued
long-term amiodarone treatment for a mean follow-up pe-
riod of 14.2 months with no recurrence of spontaneous
ventricular tachycardia. Ventricular tachycardia or ventric-
ular fibrillation recurred in the other 21 patients at a mean
follow-up period of 5.6 ± 5.1 months. Therefore, amio-
darone infrequently prevented induction of ventricular
tachycardia by premature ventricular stimulation, but long-
term amiodarone treatment successfully prevented recur-
rences in the majority of patients who had ventricular tachy-
cardia induced during initial amiodarone administration (37).
It is possible that the maximal antiarrhythmic effects of
amiodarone were not evident when electrophysiologic stud-
ies were performed 2 to 4 weeks after starting treatment.
However, other studies (43-45) in which programmed elec-
trical stimulation was performed at longer time intervals
after initiation of amiodarone treatment have also confirmed
the observation that ventricular tachycardia induction during
electrophysiologic study does not preclude a favorable long-
term course.
Predictors of long-term success. Electrophysiologic
variables other than the ability to induce ventricular tachy-
cardia may predict long-term success of amiodarone treat-
ment (46). By using discriminant function analysis, vari-
ables that predicted long-term success of amiodarone treatment
despite induction of ventricular tachycardia at electrophys-
iologic study were the change in repetitive ventricular re-
sponse status, change in the mode of induction of ventricular
tachycardia and change in right ventricular effective refrac-
tory period or QT interval (37).
Some studies (47) support the use of electrophysiologic
testing to predict the clinical response in patients who have
ventricular tachyarrhythmias treated with amiodarone. In 69
consecutive patients with recurrent sustained ventricular
tachycardia (57 patients), symptomatic nonsustained ven-
tricular tachycardia « 30 seconds in duration, 7 patients)
or ventricular fibrillation (5 patients), programmed ventric-
ular stimulation using single, double and triple extrastimuli
delivered at multiple sites and cycle lengths was used to
initiate tachycardia. Patients were tested II to 15 days after
receiving amiodarone, essentially 800 mg/day. In 22 pa-
tients ventricular arrhythmias were no longer inducible (Group
1), while 47 patients still had the arrhythmia induced (Group
2). In Group I, 18 patients received amiodarone and another
antiarrhythmic drug. There have been no recurrences of
ventricular arrhythmia in these 22 patients; 4 died of non-
arrhythmic causes. In Group 2, 43 patients received amio-
darone alone and 4 patients received amiodarone and a sec-
ond antiarrhythmic drug. Fifteen have had a recurrence of
ventricular tachycardia or ventricular fibrillation. Three pa-
tients had out of hospital cardiac arrest and two additional
patients had syncope but without documented arrhythmia.
After a mean follow-up of 12 months, five patients in Group
2 died, three of nonarrhythmic causes and two of sudden
death.
It appears clear that when evaluating antiarrhythmic drugs
other than amiodarone, continued inducibility of the ar-
rhythmia during electrophysiologic study usually predicts a
high likelihood of recurrence (75 to 90%) (48), whereas
recurrence rate is lower (10 to 50%) in patients receiving
amiodarone with similar electrophysiologic results. The ex-
planation for this difference is unclear. In some patients this
may be due to suppression of premature complexes that
precipitate the tachyarrhythmia.
Adverse Effects
General Incidence
Photosensitivity. In 140 patients treated with amioda-
rone (mean daily dose 360 mg, range 100 to 1,200) over a
5 year period (average duration of follow-up, 2 years), pho-
tosensitivity varying from increased propensity to sun tan
during the summer months to intense burning, erythema and
swelling of sun-exposed areas was the most common ad-
verse reaction (57%), based on data from patients respond-
ing to a questionnaire (30). Neither dosage nor plasma drug
concentrations proved useful in distinguishing patients with
and without photosensitivity. Dose reduction partially al-
leviated this reaction in some patients while others obtained
some relief with sun screen barrier creams. No patients
stopped the drug because of this reaction. Two patients
developing slate-gray pigmentation had been using 600 mg/day
for 5 and 2 years, respectively, and had plasma concentra-
tions of amiodarone of 3. I p,g/ml. Pigmentation decreased
gradually over a 6 to 12 month period after discontinuation
of therapy. Six patients in the first weeks of therapy de-
veloped an erythematous, pruritic rash predominantly over
the trunk.
Thyroid, gastrointestinal, ocular and neuromotor ef-
fects. Two patients developed obvious clinical findings of
hypothyroidism. Thirty-one percent of patients reported gas-
trointestinal effects, including nausea and loss of appetite
during the initial loading phase and alterations in bowel
habits with a tendency to subsequent constipation. Bio-
chemical alterations in hepatic function tests were common
although no patient developed clinically evident hepatic
dysfunction.
One patient developed pulmonary interstitial changes but
the relation to amiodarone was questionable.
Corneal microdeposits were found as early as 10 days
after starting amiodarone and were present in all patients
examined after 1 month of therapy. Two patients com-
plained of blue-green halos on looking at bright lights that
disappeared within 2 months of dose reduction. Because
percents are based on response to a questionnaire, some bias
must be anticipated because patients experiencing problems
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may have a greater motivation to respond to the question-
naire than those who are asymptomatic (30).
In another study of51 patients (43), 2 patients developed
clinical hepatitis while taking amiodarone. No patient de-
veloped peripheral neuropathy; however, 30% had a fine
tremor of hands, 28% had sleep disturbance and 14% had
headaches. All complaints responded to a reduction in dos-
age. Proximal muscle weakness occurred in eight patients
during the initial loading phase. In this regard, a sensori-
motor neuropathy has been reported with segmental de-
myelination of nerve fibers by histologic examination (49,50).
Resolution of the neuropathy occurs with discontinuation
of treatment, but his may be slow and incomplete.
Long-term side effects. In a study (51) of 70 consec-
utive patients treated with oral amiodarone, 1,200 mg for
7 days and 600 mg daily thereafter, and having at least 6
months of follow-up (mean II), side effects occurred in
93% of patients but only 19% had to discontinue their med-
ication. Fifty-six patients had gastrointestinal side effects,
most commonly constipation. All but one patient eventually
developed corneal microdeposits. Cardiovascular side ef-
fects were uncommon, while symptomatic pulmonary side
effects occurred in seven patients with pulmonary toxicity
in five. Neurologic side effects occurred in 52 patients, most
commonly tremor and ataxia. Thyroid dysfunction occurred
in 3 patients and 32 patients had skin abnormalities.
Relation to red blood cell drug and metabolite con-
centrations. In our study (23), adverse side effects during
chronic amiodarone therapy were related most strongly to
red blood cell drug and metabolite concentrations. The group
with adverse side effects had significantly higher red blood
cell concentrations of amiodarone (1. 5 versus 0.75 iLg/ml,
probability [p] < 0.001) than the patients free of adverse
effects. The occurrence of pulmonary toxicity from amio-
darone was not related to duration of treatment or cumulative
dose of drug in eight patients who had received amiodarone
from 2 weeks to 30 months with a total cumulative dose
ranging from 11.2 to 396 g. At the time of development of
pulmonary toxicity, each patient was receiving 800 mg/day.
Blue skin discoloration occurred in 17 (36%) of 53 patients
treated longer than 17 months and may relate to the cu-
mulative dose of amiodarone. Lung concentration of amio-
darone in a single patient with pulmonary toxicity was con-
siderably higher than that found in an unaffected patient
(23). Patients who have skin discoloration have higher con-
centrations of amiodarone and desethylamiodarone in af-
fected areas compared with unaffected areas (21). Four pa-
tients required pacemakers for symptomatic bradycardia.
Drug Interactions
Warfarin. Amiodarone interacts with other drugs. It po-
tentiates the anticoagulant effect of warfarin (52-55). Pro-
longation of prothrombin time may occur as early as 3 to
4 days after starting amiodarone therapy or be delayed as
long as 3 weeks. The potentiating effect persists for weeks
or months (56). The effect of amiodarone on prothrombin
activity appears to be dose-dependent, but the mechanism
is not clear. Maintenance doses of warfarin may be reduced
by a third or a half when amiodarone is begun. Amiodarone
may also influence heparin activity (55).
Digoxin. Amiodarone increases serum digoxin concen-
tration within 24 hours after dosing. Digoxin concentrations
rise linearly for 6 to 7 days and then plateau. The magnitude
of the interaction appears to be dose-related (57) and cor-
relates with plasma concentration of amiodarone (58). The
mechanism is not clear but may be due to reduction of
elimination of digoxin by renal tubular secretion. Other
mechanisms include a decrease in extrarenal excretion and
tissue displacement of digoxin by amiodarone. Serum dig-
oxin levels usually double when amiodarone is given (55).
Other antiarrhythmic agents. Amiodarone can interact
with other antiarrhythmic agents and can aggravate or ini-
tiate serious arrhythmias such as torsade de pointes, but
appears to do so less often than most other class I antiar-
rhythmic drugs (37-42). Amiodarone may increase the serum
concentration of quinidine along with an increase in QT
prolongation in patients treated with amiodarone who are
already receiving quinidine (59). Similar increases in aprin-
dine (60) and procainamide (61) concentrations have been
found when these drugs were given in conjunction with
amiodarone. The dose of the second antiarrhythmic agent
probably should be reduced by 50%.
Amiodarone may have additive effects with drugs that
exert similar actions, such as producing sinus nodal slowing
during concomitant administration of beta-adrenergic re-
ceptor blockers (62) or slow calcium channel blockers. Hy-
potension and atropine-resistant bradycardia may occur dur-
ing surgery (63).
Ocular Side Effects
Ocular deposits are bilateral and symmetrical, and de-
pend on dosage and duration of treatment. In one study
(64),98% of 103 patients treated with oral amiodarone and
followed up for periods of longer than 3 months developed
the characteristic keratopathy. Earliest changes resemble a
gray or brownish linear mark on the cornea running ap-
proximately horizontally at about the junction of the middle
and lower thirds of the cornea and not reaching the limbus.
The deposits then become more granular, grayish or brown
tinted lines radiating outward in a curved fashion from the
center point of the interpalpebral zone toward and often
reaching the limbus. On further deposition, more lines form
in similar but increasingly complex patterns resembling a
vortex or whorl. Finally, more advanced changes produce
a granular "dusting" of the whole corneal epithelium (64).
Changes are superficial and localized to the corneal epithe-
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lium. Visual symptoms are uncommon, and occurred in 6%
of 103 patients followed up from 3 months to nearly 10
years. Of these patients 3% noticed photophobia, 2% had
halos and I % complained of blurring of vision. Drug dis-
continuation or reduction of therapy was not necessary.
Sixteen patients whose drug was discontinued for other rea-
sons showed complete regression of the pattern of deposits
in 3 to 7 months. Microdeposits may occur after only 3 to
4 weeks of treatment with less than 9 g of amiodarone. No
color vision defects, dry eyes or intraocular pressure changes
were attributable to amiodarone. Irritation of the eyelids
may represent skin sensitivity rather than ocular effects (64).
No evidence suggests that amiodarone induces a retinopathy
as does chloroquine, for example. However, changes sim-
ilar to those produced by amiodarone are produced by sev-
eral other drugs (65).
Pulmonary Side Effects
Pulmonary alveolitis. Of the extracardiac side effects
produced by amiodarone, the most serious is pulmonary
alveolitis (12,66-70). In our study of 196 patients (37),
amiodarone treatment resulted in pulmonary toxicity in 7,
as evidenced by diffuse pulmonary interstitial infiltrates con-
firmed by histologic findings to be consistent with fibrosing
alveolitis in 6 patients and by a strongly positive gallium
radionuclide lung scan in the other patient. These seven
patients had received amiodarone for a period ranging from
2 weeks to 30 months before the recognition of pulmonary
abnormalities. Pulmonary abnormalities were discovered at
postmortem examination in one patient who died from
congestive heart failure, and in another patient pulmonary
abnormalities were noted 2 weeks after amiodarone was
discontinued because of recurrent ventricular tachycardia.
After amiodarone was discontinued, one patient died from
progressive pulmonary insufficiency and heart failure and
one patient died secondary to heart failure and sepsis. Three
patients were treated with glucocorticoids, one patient re-
ceived no immunosuppressive treatment and all four have
had symptomatic and roentgenographic improvement.
Clinical features. Patients with pulmonary toxicity
complain of exertional dyspnea, nonproductive cough and
weight loss but only occasionally low grade fever. Pleuritic
pain is uncommon. Physical findings usually reveal basilar
rales or decreased breath sounds and rarely a pleural friction
rub. X-ray findings generally indicate diffuse bilateral in-
terstitial changes and patchy or diffuse alveolar infiltrates,
commonly suggesting the presence of pulmonary edema,
pneumonitis or tuberculosis. Rarely pleural effusion or areas
of pleural thickening may be found. Patients may demon-
strate hypoxia, restrictive changes with reduction in total
lung capacity and diffusion abnormalities (68). In a prelim-
inary study (67), serial changes in pulmonary function tests
provided no predictive evidence for the development of
pulmonary toxicity.
Pulmonary changes have been noted to resolve on with-
drawal of amiodarone alone or on reduction of the dose.
Improvement has occurred with and without the addition of
steroid therapy. One patient who initially developed pul-
monary complications while receiving amiodarone had
regression of changes when the drug was discontinued and
developed no new changes when the drug was reinstituted
(67).
Mechanism of toxicity. Amiodarone-induced pulmo-
nary toxicity appears to be related to the doses used because
the majority of patients developing this complication have
received amiodarone maintenance doses exceeding 400 to
600 mg/day (71). The mechanism of amiodarone-induced
pulmonary toxicity has not been established. Changes may
be related to the amphiphilic nature of the amiodarone mol-
ecule that contains both a highly apolar aromatic ring system
and a polar side chain with a positively charged nitrogen
atom. The drug may bind to phospholipids and inhibit their
normal enzymatic degradation, resulting in their accumu-
lation in Iysosomes. The lung is a major site of phospholipid
synthesis and turnover and would therefore be expected to
show high concentrations of retained phospholipid (68,72,73).
Incidence. The frequency of pulmonary toxicity ranges
from 0 to about 6%. Of 39 reported cases, 9 patients died
and 30 had resolution of respiratory symptoms and radio-
logic abnormalities after withdrawal of amiodarone. Half
of the patients who died and half of those who survived
have been treated with steroids (67).
Thyroid Side Effects
Mechanism. Amiodarone has two atoms of iodine that
compose 37% of the total molecular weight of the com-
pound, or 75 mg of organic iodine1200 mg of active drug.
About 10% of organic iodine may be deiodinated to yield
free iodine, producing an amount that greatly exceeds the
daily intake of iodine (0.5 to 1.0 mg) in the average Amer-
ican diet. Several features of the drug's action on the heart
resemble those produced by hypothyroidism and it is pos-
sible that the drug exerts part of its antiarrhythmic effect
by selectively inhibiting the action of 3,5,3' -triiodothyro-
nine (T3) on the myocardium by blocking the peripheral
conversion of 3,5,3' ,5'-tetraiodothyronine (T4) to T3 (74).
Amiodarone treatment results in significant elevations of
T4 and reverse T3 with minor decreases in T3 . Thyroid-
stimulating hormone (rSH) levels may increase transiently
but thyroid binding globulin remains unchanged (75,76).
Serum reverse T3 levels may provide a basis for judging the
magnitude of in vivo drug accumulation by correlating with
the therapeutic response of the drug and the serious adverse
effects. Reverse T3 has been reliable in one study (74) for
monitoring the time course of the onset of drug action, the
establishment of efficacy and the development of toxicity
because an increase in reverse T3 occurs as a function of
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drug dose and duration of therapy, There is no evidence to
suggest that reverse T3 exerts an antiarrhythmic effect nor
that the toxicity of amiodarone is mediated by elevated levels
of reversed T3 (74),
Clinical features. Changes in thyroid function are not
accountable by the iodine contained in the drug molecule
because an amount of inorganic iodine equivalent to that
found in amiodarone produces only slightly lower levels
than normal of reverse T3 , T3 and T4 (75,76), Recovery of
normal thyroid indexes after drug withdrawal is slow and
may exceed 6 weeks. Despite the increase in total T4 , free
T4 and the free thyroxin index, heart rate is reduced by
amiodarone in all patients.
Although the clinical changes in thyroid function are not
the result of the iodine contained in the drug, it is possible
that the development of clinically significant hypothyroid-
ism or hyperthyroidism does result from the iodine contained
in the drug and not from the direct pharmacologic actions
of amiodarone (77 ,78). The frequency of amiodarone-in-
duced thyrotoxicosis varies from I to 5% (79), but may be
greater in patients with thyroid goiter induced by iodine
deficiency. The determination of serum free T3 levels and
evaluation of clinical features based on medical history and
physical examination are necessary to distinguish iodide-
induced thyrotoxicosis from an alteration in the hormone
metabolism in an otherwise euthyroid patient. Administra-
tion of thyrotropin-releasing hormone is useful because it
fails to increase thyroid-stimulating hormone in patients with
thyrotoxicosis. Development of thyrotoxicosis during amio-
darone therapy may lead to the recrudescence of arrhythmia
or angina that was present before initial therapy.
Hypothyroidism may occur in I to 2% of all patients
treated with long-term amiodarone and results in a clinical
picture indistinguishable from that of hypothyroidism due
to other causes. Reverse T3 and T4 levels fail to increase
during hypothyroidism; T3 and T4 concentrations decrease
significantly while serum TSH levels increase.
Conclusions
Amiodarone is a unique antiarrhythmic agent, in part
because of its interesting pharmacokinetics, wide range of
efficacy and array of side effects. It appears to be one of
the most effective antiarrhythmic drugs available today.
Nevertheless, it is important that physicians be aware of
amiodarone's unique characteristics so that the drug is used
properly in patients whose arrhythmias really require
suppression. Most clinical experience with amiodarone in
the United States relates to using this drug in high doses in
patients with drug-resistant serious arrhythmias. It is quite
possible that, when used in less difficult situations, lower
doses and therefore fewer side effects might result.
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